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With the changing distribution of infectious diseases, and an increase in the burden of non-communicable diseases, low- and
middle-income countries, including those in Africa, will need to expand their health care capacities to effectively respond to
these epidemiological transitions. The interrelated risk factors for chronic infectious and non-communicable diseases and the
need for long-term disease management, argue for combined strategies to understand their underlying causes and to design
strategies for effective prevention and long-term care. Through multidisciplinary research and implementation partnerships,
we advocate an integrated approach for research and healthcare for chronic diseases in Africa.
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Burden of non-communicable diseases (NCDs) in
Africa
ChronicNCDssuchasdiabetes, cardiovasculardiseases (CVD),
andcancersareemerging as leadingcausesofmortalityandmor-
bidity inAfrica. In this region,with a populationof around1.1bil-
lion, there were an estimated 28 million adults living with
diabetes in 2015 [1, 2]. It is anticipated that in sub-Saharan
Africa (SSA) alone, the number of people living with the disease
will rise to34.2millionby2040 [2]. Similarly, in2015, aprojected
1.6 million deaths were attributable to CVD in Africa [3]. This
figure is expected to rise by another 1 million by 2030 [3].
Cancer-related deaths are also anticipated to double to 1.2 mil-
lion by 2030 [3]. Close to one-third of NCD-related deaths in
low- and middle-income countries (LMICs) are premature and
occur before the age of 60 [4]. Thus, NCDs already present a
major health burden for theAfrican continent and are expected
tobethemostcommoncauseofdeath,exceeding thenumberof
deaths from communicable, maternal, perinatal, and nutritional
diseases combined, by 2030 [5].
Risk factors for NCDs in Africa
Because of the diverse social, environmental, and biological set-
tings withinAfrica, the distributions of known and other poten-
tially novel risk factors, and their determinants, are likely to
differ from those of European populations or those of
African descent living outside Africa [6]. The higher incidence
of certain cancers, such as liver, cervical and oesophageal, in
Africa compared with high-income countries (HICs) may re-
flect underlying differences in their risk factors in these regions
[7]. Population growth and the concomitant rise in life expect-
ancy are likely to only partly explain the increase in NCDs.
Many of the known risk factors for NCDs in HICs are the
same for LMICs, including smoking, alcohol, diet, obesity, raised
cholesterol and blood pressure [8, 9]. However, the distribu-
tionand relative contributionof these risk factors to theburden
of NCDs in Africa are unclear. We also have only a limited
understanding of the social, environmental and biological dri-
vers of these risk factors within African populations. Rapid ur-
banisation and globalisation, and the associated trends towards
unhealthy lifestyles, contribute to the burden of NCDs [10].
Small increases in urbanisation are associated with lower
levels of physical activity and higher body mass index [11–13].
Globalisation has increased the availability of cheap, nutrient-
poor, and energy-dense foods, which are likely to increase
the risk of obesity and associated cardiometabolic risk factors
[14]. Notably, the high burden of NCDs in rural areas, as
well as urban centres, suggest there may be additional contrib-
uting or distinct factors [15].
Impact of maternal and childhood health on NCDs
in Africa
Maternal and neonatal health and risk of NCDs are interre-
lated. The prevalence of overweight and obesity in adult
women in Africa has been rising; between 1980 and 2013,
the burden of overweight and obesity in females increased
by an average of 10% [16]. Maternal obesity increases the
risk of developing gestational diabetes [17], and is associated
with poor maternal and neonatal outcomes [18–20].
Women who develop diabetes and hypertension during
pregnancy have an increased risk of type 2 diabetes (T2D),
CVD, and metabolic syndromes [19, 21–23]. Children of
obese or diabetic mothers also have a higher risk of meta-
bolic disease in later life [24]. By contrast, under-nutrition
in utero or in early life may also result in an increased risk
of T2D and CVD in adulthood [25–28]. Adaptive responses
to exposures in utero are thought to prepare the foetus for
the postnatal environment [25]. Rapid changes in the nutri-
tional environments, as seen in many LMICs, could lead to
an increase in NCDs [25–27]. These maternal and develop-
mental risk factors may have a social, environmental, or bio-
logical basis, and are intergenerational – highlighting the
complexity of the epidemiological transitions across the
African continent, and in other LMICs [28, 29, 30].
Changing burden of infectious disease in Africa
Substantial progress has been made in reducing the burden
of many types of infectious diseases, including those in early
childhood. However, tuberculosis (TB), malaria, and HIV, as
well as hepatitis B and C, remain endemic across the region.
Africa has the highest burden of HIV in the world, with ap-
proximately 26 million prevalent cases and 1.3 million new
infections recorded in 2014 [31]. TB and HIV co-infection
is a growing issue in many LMICs [32]; as such, it is the
most common cause of death for people with AIDS [33].
Anti-retroviral therapy (ART) coverage in Africa has rapidly
increased over the past decade; 51% of known cases in SSA
received treatment in 2012 [34]. Expanding use of ART has
led to a notable decline in HIV-associated morbidity and
mortality in Africa; HIV is rapidly becoming a chronic dis-
ease, requiring long-term treatment and management. This
and the emergence of drug resistant strains of HIV, malaria,
TB, and other pathogens pose a major challenge for the con-
tinent’s infectious disease control and management pro-
grammes, which may also have implications for the burden
of NCDs [35, 36].
Interrelationship between non-communicable and
infectious disease in Africa
The interrelated risk factors for infectious and non-commu-
nicable diseases are likely to have an important impact on the
spectrum and distribution of chronic diseases in Africa, and
other LMICs undergoing similar epidemiological transitions.
The immune and metabolic systems are closely integrated,
with each system’s response dependent on the other for nor-
mal function [37]. Evolving from a common antecedent organ,
they have shared and overlapping signalling pathways [37].
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Chronic inflammation has been unequivocally linked to
obesity, insulin resistance, T2D, and an increased risk of
malignancy [37, 38]. Likewise, several infectious diseases
and their treatments are associated with an increased risk
of NCDs [39]. HIV and ART may increase the burden of
cardiometabolic risk factors, including lipid and glucose
abnormalities [40–43]. Hepatitis B and C infection may also
increase the riskof developingT2D [44–46], aswell as chronic
liver disease and hepatocellular cancers, in addition to other
oncogenic pathogens [47]. Similarly, insulin resistance and
T2D may influence clinical outcomes in patients with
hepatitis-associated liver disease and cancer [48]. Endemic in-
fectious diseases may have also had an impact on selective
adaptation and risk of NCDs – for example, renal function
and African trypanosomiasis [49]. Thus, the body’s own im-
mune response, endemic and chronic infections, and their
treatments, may play an important role in the development
and progression of NCDs in Africa, although the underlying
mechanisms are not well understood.
The need for surveillance and prospective studies
in Africa
Understanding the aetiology and determinants of NCDs in
Africa is a fundamental step in developing strategies for dis-
ease prevention, management and control. Crucially, the im-
pact of population and individual risk factors on disease
susceptibility is largely unknown. Usually, chronic disease
risk prediction models applied to African populations are
based on regional comparisons of national indices, cross-
sectional or case-control assessments, and the extrapolation
of risk prediction algorithms developed in populations in
Europe and elsewhere [50–52]. Furthermore, those studies
conducted in African populations often use varying methods
and definitions, or only assess a small subset of potential risk
factors, limiting comparative analysis [53–55].
Whilst research institutions in Africa have clearly devel-
oped research frameworks for assessing the epidemiological
and clinical burden of chronic disease across the region,
there is a need to integrate and scale up such efforts [6,
40, 51, 56]. The INDEPTH Network of health and demo-
graphic surveillance systems is an example of a pragmatic
model for examining disease burden across different settings
[57–59]. Utilizing such established surveillance systems and
analogous research initiatives to implement high quality
and comparable large-scale population-based studies across
the spectrum of chronic diseases and their risk factors will
be crucial to understanding the aetiology and burden of
chronic diseases in Africa. Likewise, implementation of stan-
dardised tools for the measurement of NCD risk factors in
LMICs, such as those developed by the WHO, will enable
comparability [60]. Importantly, establishing prospective
studies in these settings will provide an invaluable frame-
work to evaluate the utility of existing generic cut-off points
or develop specific risk prediction algorithms for African
populations, and provide the foundations for future aetio-
logical and healthcare interventions.
The need for research into the implementation of
integrated health services and the management of
chronic diseases in Africa
Aligning epidemiological and implementation research will
provide the most effective strategy to identify pragmatic
solutions for delivering chronic disease health care. The
emerging double burden of chronic infectious and non-
communicable disease imposes a substantial strain on lim-
ited healthcare resources and has implications for health
policy and planning. In many African countries, where health
systems are fragile, under-resourced or targeted primarily
to infectious diseases, the capacity to effectively deal with
the burden of chronic NCDs and accompanying co-
morbidities is severely limited [61, 62]. These health system
challenges will only become more apparent as the preva-
lence of NCDs increases.
Chronic infectious and non-communicable disease pro-
grammes in Africa have traditionally been distinct at all levels
of healthcare provision. However, emerging evidence sug-
gests that an integrated approach to the broad spectrum
of chronic diseases may provide the most cost-effective
mechanism for disease treatment and control due to the
related underlying pathogenesis and strategies for manage-
ment [63, 64]. Integrating NCD management with existing
HIV/AIDS/TB, malaria, and maternal and child health pro-
grammes would utilise existing infrastructure, and allow
for more rapid implementation of NCD health care [65].
Ideally these services would be placed within a strengthened
and well-resourced primary health care system that can pro-
vide pro-active, patient-centric and long-term community-
based care [66]. However, a more complete understanding
of the broad range of risk factors, and their interrelation,
will be critical in designing such integrated health care sys-
tems – and provide mechanisms for broader preventative
strategies. In these contexts, it is vital to conduct public
health implementation research to fully explore the most
effective and economic strategies to deliver accessible and
integrated health care for chronic diseases [67–70].
Universal implementation of existing low cost interventions
for the diagnosis and management of NCDs and infectious
diseases would be a pivotal first phase [66].
Likewise, it will be important to identify the most effective
strategies for chronic disease management for the African
context; reliable information on the efficacy of drug treat-
ments for NCDs and infectious diseases, and their adverse
reactions in African populations is limited [71, 72].
Harnessing and integrating existing health and pharmacovigi-
lance systems could also facilitate drug efficacy trials and
monitoring. Evaluation of current and novel chronic disease
diagnostics, treatment and management strategies, including
point of care testing and low-cost technology-based
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interventions within resource-limited settings, will be vital
to implementing efficient mechanisms for integrated chronic
disease research and care across the region, and in translating
research findings into health care policy and services [73, 74].
An integrated approach to chronic disease
research and care in Africa
NCDs and infectious diseases should not be viewed as dis-
tinctive fields within global health research [75]. There is a
critical need to combine research efforts across both
acute and chronic infectious diseases and NCDs to better
understand their interrelation and to develop more effective
health systems to provide long-term management and care.
Research and implementation partnerships will need to
adopt innovative multidisciplinary research agendas that
both strengthen and integrate existing infrastructure and ad-
vance implementation science. Combined, such structures
could allow the formation of large-scale population health
resources that would enable comprehensive studies into the
diagnosis, prevention and management of chronic diseases,
and their complex interactions, over diverse settings [76].
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